OrbiMed’s Post

🌬️ Advancing COPD Therapies with Biocytogen's Fully Human Antibody Library Chronic obstructive pulmonary disease (COPD) affects millions worldwide, leading to shortness of breath, excessive mucus, and coughing due to airflow obstruction caused by chronic bronchitis and/or emphysema. While traditional treatments like bronchodilators and corticosteroids help manage symptoms, they often fall short in addressing individual variability and chronic complications, underscoring the urgent need for innovative therapies. At Biocytogen, we’re pushing the boundaries of COPD treatment with RenBiologics™, our sub-brand featuring an off-the-shelf library of over 400,000 fully human antibody sequences against 1,000+ targets—including COPD-related ones like IGHE, MET, and ST2 antibodies. Let’s transform the future of COPD care together! 🌟 Read more: https://lnkd.in/epgRdAMM #COPD #Biocytogen #RenBiologics #FullyHumanAntibodies #BiotechInnovation #DrugDevelopment

Advance view of our ATS abstracts Here are some preliminary data from DISA trial Prospective evaluation of Dupilumab on serial mannitol challenge in T2 high severe asthma Here we show statistically significant and clinically relevant improvements in airway hyper responsiveness (AHR) over 12 weeks The lower 95%CI for the doubling difference in mannitol AHR after 12 weeks exceeded 1 dd This was accompanied by clinically relevant improvements in asthma control and quality of life In addition lung function measures of small airways dysfunction were ameliorated to a clinically relevant degree Finally BDP/FM MART use from the dose counter was sig reduced by 1 puff/day indicating ICS sparing activity Conclusion Dupilumab conferred clinically important changes in AHR accompanied by commensurate improvements in asthma control and small airways function .

Management goals for patients with COPD include reduction of symptoms, improvement in lung function, and prevention of exacerbations. Explore underlying disease mechanisms and biologics in COPD in this free #CME activity: https://bit.ly/4d0Mg1z #MedEd #FOAMed

Some very good news for people with asthma and COPD. The first new treatment for acute attacks in over 50 years— a monoclonal antibody vs interleukin-5 receptor-α—with efficacy in a randomized trial https://lnkd.in/gyygRbZC

Fantastic news! The introduction of a monoclonal antibody targeting interleukin-5 receptor-α, with proven efficacy in trials, is a game-changer after 50 years. Excited to see the positive impact it will have on moving the needle in the prevention space of COPD/ asthma.

The introduction of a monoclonal antibody, Benarlizumab, targeting interleukin-5 receptor alpha which means treating an asthma exacerbation in an acute setting with proven efficacy in randomised clinical trials, is surely a game changer after 50 years in the COPD/ Asthma treatment space. Worth mentioning that this is not a new mAb and might probably be the first time a monoclonal antibody has been shown to be effective in asthma treatment.

I read this with great interest, especially as an asthmatic who is constantly on the lookout for better treatments that could potentially move beyond management to a true cure. The introduction of benralizumab is undoubtedly an exciting step forward, particularly for those of us dealing with eosinophilic asthma or COPD. That said, I think it’s important to examine the study’s findings critically. While the trial shows promising results, a few aspects raise questions: Pooling of Data: The researchers combined outcomes from patients receiving benralizumab alone with those receiving benralizumab plus prednisolone. This makes it difficult to assess the standalone effectiveness of the drug and whether it truly outperforms existing therapies. Short Follow-Up Period: The 90-day timeframe limits our understanding of long-term impacts, such as reductions in exacerbation rates over years or the potential for rare but serious side effects. The Broader Picture: Speaking as an asthmatic, I can’t help but feel that the ongoing consumable market for inhalers and other maintenance medications plays a role in why we have yet to see a truly curative treatment for asthma. Innovations like benralizumab are welcome, but they remain part of a management paradigm rather than a cure. I hope this marks the beginning of a new era where we see more investment in treatments that go beyond symptom management to fundamentally change the course of asthma and COPD

Great to finally see some innovation for treatment of patients with COPD and asthma flares.

Cost per patient in the idea below - well actually the asthmatic ***MAKES*** money rather than handing over money to the ghastly medical establishment. 'These results indicate that increasing systemic BHB concentrations through dietary interventions could provide symptom relief for several endotypes of allergic asthmatics through effects on bronchial smooth muscle cells.' Explanation - general pattern of decreasing over-excitability when in deep keto vs the hyper/hypo glycaemic rollercoaster /cf/ epilepsy where all of this has been worked up - allbeit in Neuro rather than Muscular. file:///C:/Users/bhatt/Downloads/fastiggi-et-al-2023-beta-hydroxybutyrate-attenuates-aeroallergen-induced-responses-by-bronchial-smooth-muscle.pdf

#Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease. The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are 300,000 such people in the U.S., according to Regeneron and Sanofi, which jointly developed Dupixent. Market analysts estimate the new indication could bring in more than $1 billion in additional annual revenue for Dupixent. The drug has a list price of $3,803 for a one-month supply. Full story: https://trib.al/BBJDyEx